The FDA doesn’t invite you to present unless they’re paying attention. Tomorrow, Immusoft walks into an FDA/ARM co-hosted workshop to share a clinical case review on the first human being ever treated with an engineered B cell therapy. Read that again. First. Ever.

The drug is ISP-001, and it targets MPS I, a rare metabolic disorder where patients lack a critical enzyme called alpha-L-iduronidase. Without it, toxic sugars accumulate in cells and slowly wreck the body. The current standard of care is enzyme replacement therapy, which means infusions every single week for the rest of your life.

Immusoft’s pitch is different. Take the patient’s own B cells, reprogram them to produce that missing enzyme continuously, and put them back. The B cells migrate to the bone marrow, differentiate into plasma cells, and basically become tiny protein factories that never stop running. One treatment. Not weekly infusions.

The re-dosing part is quietly huge. Most gene therapies are one-shot deals. If the dose isn’t right, too bad. Immusoft’s B cell approach doesn’t trigger the immune blowback that viral vectors do, so you can go back in and give more. That’s a massive unlock for rare disease, where getting the dose right on attempt one is basically guesswork.

And there’s a backstory here worth knowing. The first patient showed a 239-meter improvement on the six-minute walk test at one year. That’s not a rounding error. That’s someone’s life changing.

Immusoft just pocketed a $15 million CIRM grant nine days ago to expand the clinical program. They’ve also got a deal with Takeda for neurometabolic applications worth up to $900 million. And they hold 60+ patents on the platform. For a company most people haven’t heard of, they’re building something that could reshape how we think about enzyme replacement entirely.

Tomorrow’s presentation won’t have blockbuster data readouts. It’s a case review. But the fact that the FDA is hosting the stage? That tells you where the wind is blowing.